CONCLUSION:
Intraprocedural MG was found to be a strong predictor for a high
12-month mortality rate (cut-off value: 4.5 mmHg) and adverse functional
outcomes (cut-off value: 3.9 mmHg), irrespective of the aetiology of MR.
In conformity, patients with an in-hospital persistent elevated MG (≥4.5
mmHg) showed the worst clinical results, including the lowest functional
capacity and the highest 12-month mortality followed by patients with an
in-hospital decrease in MG to values below 4.5 mmHg at discharge.
Additionally, MV geometry assessed by LAI (> 1.11) was the
strongest predictor for unfavourable intraprocedural MG, followed by MG
at baseline, the number of implanted clips and clip orientation (central
implantation). These parameters might help for selecting appropriate
patients, intrainterventional decision-making, and avoiding adverse MG
values resulting in more favourable clinical outcomes.
Acknowledgement: We thank Dr Meghan Campbell (scientific
coordinator in the Heart Center Bonn, University Hospital Bonn, Germany)
for proofreading the manuscript.
Funding: This research received no grant from any funding
agency in public, commercial or not-for-profit sectors.
Disclosures: Öztürk C, Sprenger Kim, Sugiura A, Weber M, Tabata
N, Schueler R have no conflict of interest. Nickenig G has received
speaker honoraria and research grants from Medtronic, Boston Scientific,
Edwards Lifesciences, and Abbott.